Type 1 diabetes: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• GLP-1 21
• SGLT2 12
• NRF2 0
• CTLA-4 0
• STAT3 0
• AKT 0
• GIP 2
• PD-1 0
• SIRT1 0
• CD40 0
• PPAR 0
• TP53 0
• JAK 1
• JNK 0
• mTOR 0
• NLRP3 1
• TLR4 0
• AMPK 0
• DPP-4 0
• IL-6 0
• TNF 0
• IL-1 0
• IL-17 0
• MAPK 0
• PI3K 0
• VEGF 1
• CD47 0
• HMGB1 0
• PD-L1 0
• ACE2 0
• BDNF 0
• CD19 0
• CD20 1
• CD38 0
• ERK 0
• FOXP3 0
• G6PD 0
• IL-13 0
• IL-4 0
• PCSK9 0
• RANKL 0
• STING 0
• TIGIT 0
• AR 0
• B7-H3 0
• CD22 0
• CTNNB1 0
• CXCR4 0
• EGFR 0
• GPX4 0
• HDAC 0
• HER2 0
• HER3 0
• HSP90 0
• IGF1R 0
• LAG-3 0
• METTL3 0
• MYC 0
• NMDA 0
• PDGFR 0

2 of 2+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIBIB · DP2

  Decoding Cell-Fate Decisions Through Molecular Recording

  Sloan-Kettering Inst Can Research· New York, United States· US$843,125 awarded in fiscal year 2026· until Jul 2031

• NIH NIDDK · F30

  Establishing the Cholinergic Anti-Inflammatory Pathway in Pancreatic Islets.

  University of Miami School of Medicine· Coral Gables, United States· US$55,114 awarded in fiscal year 2026· until Sept 2028

• NIH NCCIH · R21

  Probiotic-derived SH3b domains as effector molecules

  University of Florida· Gainesville, United States· US$397,502 awarded in fiscal year 2026· until Aug 2028

• NIH NIDDK · U01

  Mitigating Diabetic Ketoacidosis in People with T1D and Chronic Kidney Disease on an SGLT1&2 Inhibitor: Ketosis Risk Factor Determination and Incorporation into an Enhanced Glucose Ketone Report

  Healthpartners Institute· Bloomington, United States· US$1,542,828 awarded in fiscal year 2026· until Aug 2028

• NIH NIAID · R01

  Combined engineering of human stem cell-derived beta cells and regulatory T cells to treat type 1 diabetes

  Medical University of South Carolina· Charleston, United States· US$640,131 awarded in fiscal year 2026· until Aug 2031

• European Commission (Horizon Europe) · HORIZON-ERC

  Modeling islet inflammation in early-stage type 1 diabetes: T1DstartEd (T1Dstarted)

  The Hebrew University of Jerusalem· Jerusalem, Israel· EU contribution €2,796,250· until May 2032

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  The Inreda bi-hormonal blood glucose control pump: A beacon for high-risk diabetes patients, providing fully automated in disease management (DIABEACON)

  Inreda Diabetic Bv· Goor, Netherlands· EU contribution €2,499,414· until Jun 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Type 1 Diabetes Simulator with Adjunctive therapies - GLP1 (T1SIA)

  Universitat Politecnica de Valencia· Valencia, Spain· EU contribution €243,097· until Jan 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  From harassing to harnessing beta-cells in type 1 diabetes (Beta-STEALTH)

  Academisch Ziekenhuis Leiden· Leiden, Netherlands· EU contribution €2,500,000· until Oct 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Uncovering Protective Mechanisms in Pancreatic β-Cells to Enhance Their Survival in Type 1 Diabetes (Beta_cell_protection)

  Universite Libre de Bruxelles· Bruxelles, Belgium· EU contribution €200,400· until Jul 2027

10 of 636 running projects, newest first. Listed amounts together: US$464.3m + €48.3m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar

  NCT07284511· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity

  NCT06180616· Royal North Shore Hospital· Source

• The Effect of Glucose-dependent Insulinotropic Polypeptide on the Alpha Cell Response to Hypoglycaemia in Patients with Type 1 Diabetes

  NCT06137586· University Hospital, Gentofte, Copenhagen· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 10
• Organoids 4
• Mendelian Randomization Analysis 35
• CRISPR-Cas Systems 5
• Gene Expression Profiling 34
• Sequence Analysis, RNA 3
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 20
• Metabolomics 15
• Mass Spectrometry 4
• Flow Cytometry 12
• Immunohistochemistry 16
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 33
• Machine Learning 31
• Deep Learning 10
• Cohort Studies 158
• Genome-Wide Association Study 54

• Impact of diabetic foot ulcers on mortality risk: Lessons from a 35-year Brazilian cohort followed at an association of people living with diabetes.

  Arch Endocrinol Metab, Oct 2026

• Optimizing foot screening in type 1 diabetes: Evaluation of risk-adapted screening intervals (OPTI-ONE).

  J Diabetes Complications, Oct 2026

• Temporal trend analysis of the global prevalence of vision impairment and blindness attributable to diabetes from 1990 to 2021.

  Endocrine, Oct 2026

• Prevalence of Chronic Complications After Inaugural Admission in Intensive Care Unit for Type 1 Diabetes in the SFDT1 Cohort: The INAUGURAL Study.

  Diabetes Obes Metab, Oct 2026

• Evaluating the implementation of the Diabetes Body Project in a clinical cohort of Australian adolescents with type 1 diabetes.

  Front Endocrinol (Lausanne), Sept 2026

• Dietary vitamin C intake and the risk of islet autoimmunity and type 1 diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY) Study.

  Eur J Nutr, Sept 2026

• Dose-Normalised Time in Range (dn-TIR) Improves Following Hybrid Closed-Loop (HCL) Therapy in Type 1 Diabetes: A Real-World Cohort Study From Australia and the United Kingdom.

  Diabetes Obes Metab, Sept 2026

• Elevated remnant cholesterol levels and variability with incident mental disorders in adults with type 1 diabetes: a nationwide cohort study.

  J Psychosom Res, Sept 2026

• Large-scale multiethnic electronic health record resource for diabetes complications research: the North West London Diabetes Cohort (NWLDC) - cohort profile.

  BMJ Open, Sept 2026

• Serum Lipidomics Profiling Identify Novel Biomarkers of Distal Symmetrical Polyneuropathy in Type 1 Diabetes.

  Diabetes Obes Metab, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.